Park Square is pleased to announce the placement of Robert Paul, M.D., Ph.D. as a Scientific Advisory Board Member at Switch Therapeutics, a rapidly growing biotechnology company pioneering a new class of RNAi therapeutics.

Dr. Paul is a distinguished physician-scientist with a wealth of experience in the neuroscience field. He currently serves as Chief Executive Officer at Nine Square Therapeutics, a privately held developer of small molecule therapeutics to treat movement disorders. Previously, he served as Chief Medical Officer at Alector, a publicly traded company that develops therapies for the treatment of neurodegenerative disease. Prior, he served in roles of increasing responsibility at Genentech, ultimately serving as Therapeutic Area Head, Neuro Early Clinical Development. Earlier, he spent several years as a neurologist at the University of Munich and also was a consultant at Boston Consulting Group. 

Dr. Paul is a board-certified neurologist in Germany and holds an M.D. and a Ph.D. from Ludwig-Maximilians Universität München.